By reducing LDL-C content, inhibiting PA and thrombosis, and reducing the production of inflammatory substances, PCSK9 can treat hyperlipidemia [106], As [107], lipoprotein(a) [108], venous thromboembolism (VTE) risk [109], aortic stenosis [110] and other cardiovascular diseases. This evidence concerns the gene PCSK9 and aortic stenosis.